Panoramica dell'azienda
BioHarvest Sciences Inc. operates as a biotechnology entity with a primary footprint in Israel and the United States, leveraging a botanical synthesis platform technology to manufacture plant cells containing elevated concentrations of active ingredients. The company is positioned within the Consumer Defensive sector, specifically categorized under the Packaged Foods industry, a classification that typically denotes businesses providing essential goods with demand that is relatively stable regardless of economic cycles. According to the latest available data, BioHarvest Sciences Inc. holds a market capitalization of $97.70M and reports annual revenue of $34.51M, while employing a workforce of 89 individuals. These valuation and revenue figures indicate that the company operates on a mid-cap scale, suggesting it has established a presence in the market but has not yet achieved the massive scale associated with large-cap industry leaders, a position often characterized by higher growth potential but also greater operational risk. The combination of its specialized technology and its placement in the defensive sector implies a strategic focus on producing ingredients that may offer resilience against broader market volatility.
Salute finanziaria
The company reported a revenue of $34.51M over the trailing twelve months, yet recorded a net income of $-11,135,000 and an EBITDA of $-5,111,000. The significant disparity between the positive revenue figure and the substantial net loss reveals a cost structure where operating expenses and other deductions far exceed the gross profits generated from sales, resulting in a bottom-line deficit that is more than double the EBITDA loss. Free cash flow stands at $-10,782,250, indicating that the company is currently consuming cash reserves to fund its operations and growth initiatives, which limits immediate financial flexibility and suggests a reliance on external capital or existing liquidity to sustain activities. Margin analysis shows a Gross Margin of 59.3%, which indicates that the company retains a healthy portion of revenue after direct production costs, though this is offset by an Operating Margin of -12.4% and a Profit Margin of -32.3%, both of which highlight significant inefficiencies or high overhead costs in the broader operational picture. On the balance sheet, the company holds $23.04M in cash against $14.10M in debt, resulting in a Debt to Equity ratio of 55.42, which suggests a leveraged position where debt obligations are significant relative to shareholders' equity. Despite the leverage, the Current Ratio is 3.97, a metric that indicates strong short-term liquidity and an ability to cover current liabilities with current assets well in excess of a safe threshold. Return on Equity is reported at -83.2% and Return on Assets at -9.6%, metrics that reveal that management is currently generating negative returns on both the capital invested by shareholders and the total asset base, reflecting the challenges of scaling a biotechnology operation before profitability is achieved.
Valutazione del valore
Valuation metrics present a mixed picture for BioHarvest Sciences Inc., with a Trailing P/E Ratio (TTM) listed as N/A due to the negative net income, and a Forward P/E of -107.75, which implies that the market prices the stock based on anticipated future earnings recovery rather than current profitability. The Price to Book ratio is 3.84, suggesting that the market values the company at a significant premium over its net asset value, a scenario often seen in biotech firms where intangible assets and future growth prospects outweigh the book value of tangible assets. Alternative valuation multiples include a Price to Sales ratio of 2.83 and an EV/EBITDA of -17.37, which provide context for investors by showing how much revenue and operating cash flow the market is willing to pay relative to the current stock price. The stock has traded within a range defined by a 52-Week High of $12.80 and a 52-Week Low of $4.10, and the current price sits below the 52-week high, reflecting a period of volatility where the share price has not yet recovered to its yearly peak. The Beta value is 1.40, indicating that the stock is expected to be 40% more volatile than the broader market, meaning it is likely to experience larger swings in price during periods of market stress or rally compared to the index.
Growth & Income
Revenue growth year-over-year is recorded at 24.6%, demonstrating a strong expansion in top-line sales, whereas Earnings Growth (YoY) is N/A, highlighting that the company is currently unprofitable and therefore earnings are not growing in the traditional sense but rather moving from deep losses toward break-even. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute income to shareholders, which implies that all generated cash and retained earnings are being reinvested into the business to fund research, development, and operational scaling rather than providing income streams. This reinvestment strategy is typical for biotechnology companies in the early to mid-stages of their lifecycle, where capital allocation focuses on achieving commercialization milestones rather than rewarding shareholders with dividends. Consequently, the overall growth and income profile for BioHarvest Sciences Inc. is characterized by significant top-line expansion and zero current income distribution, positioning the stock as a pure play on future operational success rather than a current income generator.